Ahead of World Aids Day and as part of its continued commitment to ensuring access to quality, affordable antiretrovirals (ARV), Cipla launched its new triple-combination ARV treatment for HIV in South Africa. The new combination medicine, Reydin, is a combination of tenofovir (TDF), lamivudine (3TC) and dolutegravir (DTG) and was approved by the South African Health Products Regulatory Authority (SAHPRA) in September 2018.
This new fixed-dose combination, Reydin - an addition to Cipla's comprehensive portfolio of HIV medication - is recommended by the World Health Organisation (WHO) as the preferred first-line regimen for managing HIV.
Cipla South Africa CEO, Paul Miller, said: "We're always focused on ensuring that patients benefit by having access to quality, affordable ARVs. DTG is considered a best-in-class medicine providing many clinical benefits for people living with HIV. With DTG replacing efavirenz (EFV) in the first-line fixed dose combination treatment thus reducing the likelihood of treatment failure, Reydin has the potential to reduce overall treatment costs."
According to UNAIDS, "Antiretroviral therapy using dolutegravir has several advantages over other regimens, including clinical superiority, improved side-effect profile, and reduced risk of viral resistance."
Reydin - currently produced in India - will be manufactured at Cipla's facilities in Durban and Uganda, reinforcing Cipla's commitment to produce medicines in Africa for Africa and ensuring more affordable treatment for patients. Cipla will continue to work closely with government through tender submissions to ensure that people have access to quality, affordable treatment.
Cipla has a legacy of pioneering affordable ARVs: in 2001, it produced the world-first three-in-one fixed combination drug, available at less than $1 per day. This enabled countless patients to have access to life-saving medication. The launch of Reydin continues this commitment.